drugset / Trial / NCT02312089

GnRHa for Luteal Phase Support in GnRH Antagonist Protocol Cycles

NCT02312089

Phase 4 Unknown 200 enrolled Mansoura University
RandomizedParallel-groupOpen-labelSupportive care

Summary

Evaluation of the effect of adding a single dose of gonadotropin releasing hormone agonist (GnRHa) as a luteal phase support on the outcomes of intracytoplasmic sperm injection (ICSI) following GnRH antagonist protocol

Timeline

Start
2016-08-07
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Triptorelin Other / unclassified 0.2 mg Subcutaneous

Indications